{
    "nct_id": "NCT06119217",
    "official_title": "An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients Not Previously Treated for Metastatic Pancreatic Adenocarcinoma",
    "inclusion_criteria": "1. Age 18 years or older, is willing and able to provide informed consent\n2. Histologically or cytologically confirmed diagnosis of metastatic PDAC.\n3. No prior systemic treatment for metastatic disease.\n4. Evidence of measurable disease per RECIST 1.1.\n5. Appropriate for treatment with nab-paclitaxel and gemcitabine chemotherapy.\n6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n\nAbbreviated\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. History of clinically significant allergy or hypersensitivity to planned study treatment components or to any monoclonal antibody\n2. Use of investigational agent within 14 days prior to the first dose of study drug\n3. History of autoimmune disease\n4. Subject has received live vaccine within 28 days prior to the first dose of study drug\n5. Has uncontrolled intercurrent illness",
    "miscellaneous_criteria": "Abbreviated"
}